Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMK2D | Q13557 | 5/20 | 0.81 |
| ▸ | JAK2 | O60674 | 3/20 | 0.73 |
| ▸ | JAK3 | P52333 | 1/20 | 0.73 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.67 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.67 |
| ▸ | ABL1 | P00519 | 7/20 | 0.66 |
| ▸ | BCR | P11274 | 6/20 | 0.66 |
| ▸ | PRKCA | P17252 | 4/20 | 0.66 |
| ▸ | PRKCD | Q05655 | 4/20 | 0.66 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.66 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.66 |
| ▸ | SRC | P12931 | 3/20 | 0.66 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.66 |
| ▸ | PRKCG | P05129 | 1/20 | 0.66 |
| ▸ | PRKCB | P05771 | 1/20 | 0.66 |
| ▸ | PRKCH | P24723 | 1/20 | 0.66 |
| ▸ | PRKCI | P41743 | 1/20 | 0.66 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.66 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.66 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14021038 | 0.93 | CAMK2D (0.71) | CAMK2DJAK2JAK3MAPK8MAPK10 | |
| SCHEMBL4903404 | 0.89 | JAK2 (0.68) | CAMK2DJAK2JAK3MAPK8MAPK10 | |
| SCHEMBL14021028 | 0.87 | PIK3CA (0.64) | CAMK2DJAK2JAK3MAPK8MAPK10 | |
| SCHEMBL19221758 | 0.85 | CAMK2D (0.74) | CAMK2DJAK2JAK3MAPK8MAPK10 | |
| SCHEMBL4903275 | 0.85 | ABL1 (0.81) | JAK2ABL1BCRPRKCAPRKCD | |
| SCHEMBL4378752 | 0.84 | JAK2 (1.00) | CAMK2DJAK2JAK3MAPK8ABL1 | |
| SCHEMBL4383820 | 0.84 | JAK2 (1.00) | CAMK2DJAK2JAK3MAPK8MAPK10 | |
| SCHEMBL14348407 | 0.84 | CAMK2D (0.72) | CAMK2DJAK2JAK3MAPK8MAPK10 | |
| SCHEMBL13911480 | 0.84 | CAMK2D (0.68) | CAMK2DJAK2JAK3MAPK8MAPK10 | |
| SCHEMBL14021033 | 0.83 | AURKA (0.62) | CAMK2DJAK2JAK3MAPK8MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101605766-A | Pyrimidine derivatives and they are as the purposes of kinase inhibitor | CGI PHARMACEUTICALS INC (US) | 2009-12-16 | — | — | CN | claimed |
| EP-2069314-A1 | PYRIMIDINES DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | CGI Pharmaceuticals, Inc. (US) | 2009-06-17 | — | — | EP | claimed |
| US-20080125417-A1 | CERTAIN PYRIMIDINES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI PHARMACEUTICALS, INC. | 2008-05-29 | — | — | US | claimed |
| WO-2008033834-A1 | PYRIMIDINES DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | claimed |
| CN-101605766-A | Pyrimidine derivatives and they are as the purposes of kinase inhibitor | CGI PHARMACEUTICALS INC (US) | 2009-12-16 | — | — | CN | disclosed |
| EP-2069314-A1 | PYRIMIDINES DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | CGI Pharmaceuticals, Inc. (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20080125417-A1 | CERTAIN PYRIMIDINES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI PHARMACEUTICALS, INC. | 2008-05-29 | — | — | US | disclosed |
| WO-2008033834-A1 | PYRIMIDINES DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| US-7312227-B2 | Compositions useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312227-B2 | Compositions useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125417-A1 | CERTAIN PYRIMIDINES, METHOD OF MAKING, AND METHOD OF USE THEREOF | BTK, SYK, TK1 | CAMK2D 1585/4885JAK2 82/4885JAK3 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.